Characterization of Advanced <i>RAS</i> -driven Follicular-derived Thyroid Cancers and Review of Future Therapeutic Avenues
Sarah Hamidi(The University of Texas MD Anderson Cancer Center), Maria E. Cabanillas(The University of Texas MD Anderson Cancer Center), Mark Zafereo(Texas Medical Center), Sinchita Roy‐Chowdhuri(The University of Texas MD Anderson Cancer Center), Neal S. Akhave(The University of Texas MD Anderson Cancer Center), Victoria Banuchi(The University of Texas MD Anderson Cancer Center), Vicente Rodrigues Marczyk(The University of Texas MD Anderson Cancer Center), Steven G. Waguespack(The University of Texas MD Anderson Cancer Center), Naifa L. Busaidy(The University of Texas MD Anderson Cancer Center), Jennifer Wang(The University of Texas MD Anderson Cancer Center), Luana Guimarães de Sousa(The University of Texas MD Anderson Cancer Center), Anastasios Maniakas(The University of Texas MD Anderson Cancer Center), Theresa A. Guise(The University of Texas MD Anderson Cancer Center), Michelle D. Williams(The University of Texas MD Anderson Cancer Center), Mena Mansour(The University of Texas MD Anderson Cancer Center), Ramona Dadu(The University of Texas MD Anderson Cancer Center), Mimi I. Hu(The University of Texas MD Anderson Cancer Center), Steven I. Sherman(Johns Hopkins University), Marie‐Claude Hofmann(The University of Texas MD Anderson Cancer Center), Padmini Iyer(The University of Texas MD Anderson Cancer Center), Renata Ferrarotto(The University of Texas MD Anderson Cancer Center)
Cited by 5
Related Papers
Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid Cancers
|New England Journal of Medicine|2020|766
2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer
|Thyroid|2021|699
A Comparison of Recombinant Human Thyrotropin and Thyroid Hormone Withdrawal for the Detection of Thyroid Remnant or Cancer1
|The Journal of Clinical Endocrinology & Metabolism|1999|564
Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer
|Journal of Clinical Oncology|2011|551
Precision Targeted Therapy with BLU-667 for <i>RET</i>-Driven Cancers
|Cancer Discovery|2018|392